Alluvi, known as BI 4744, represents a notable breakthrough in obesity care. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling effectiveness in patient studies, possibly surpassing available GLP-1 receptor sti